PMID- 26886710
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1432-1289 (Electronic)
IS  - 0020-9554 (Linking)
VI  - 57
IP  - 3
DP  - 2016 Mar
TI  - [Current therapeutic strategies for mantle cell lymphoma].
PG  - 230-7
LID - 10.1007/s00108-016-0017-y [doi]
AB  - Mantle cell lymphoma is a subtype of B‑cell lymphoma with a mostly aggressive 
      behavior and poor long-term prognosis. The choice of therapy depends on the age, 
      performance status and risk profile of the patient. Randomized trials have 
      confirmed the superiority of a dose-intensified induction therapy containing 
      cytarabine followed by autologous stem cell transplantation in the first-line 
      treatment of younger patients with a good general condition. Elderly patients 
      benefit from a rituximab maintenance therapy after immunochemotherapy. Novel 
      targeted therapies of the B‑cell receptor pathway with the Bruton's tyrosine 
      kinase inhibitor ibrutinib and the mechanistic target of rapamycin (mTOR) 
      antagonist temsirolimus as well as immunomodulatory drugs (lenalidomide) have 
      shown promising results in relapsed disease. The proteasome inhibitor bortezomib 
      has been approved for first-line treatment in combination with conventional 
      chemotherapy.
FAU - Dreyling, M
AU  - Dreyling M
AD  - Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen, 
      Marchioninistr. 15, 81337, Munchen, Deutschland. 
      martin.dreyling@med.uni-muenchen.de.
FAU - Schnaiter, A
AU  - Schnaiter A
AD  - Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen, 
      Marchioninistr. 15, 81337, Munchen, Deutschland.
FAU - Schmidt, C
AU  - Schmidt C
AD  - Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen, 
      Marchioninistr. 15, 81337, Munchen, Deutschland.
FAU - Hoster, E
AU  - Hoster E
AD  - Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen, 
      Marchioninistr. 15, 81337, Munchen, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Aktuelle Therapiestrategien beim Mantelzelllymphom.
PL  - Germany
TA  - Internist (Berl)
JT  - Der Internist
JID - 0264620
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage
MH  - Chemoradiotherapy/*methods
MH  - Combined Modality Therapy/methods
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Lymphoma, Mantle-Cell/*pathology/*therapy
MH  - Molecular Targeted Therapy/*methods
MH  - Radiotherapy/methods
MH  - Rituximab/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Autologous transplantation
OT  - B-cell lymphoma
OT  - Immunochemotherapy
OT  - Receptor pathways
OT  - Targeted therapy
EDAT- 2016/02/18 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/18 06:00
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s00108-016-0017-y [pii]
AID - 10.1007/s00108-016-0017-y [doi]
PST - ppublish
SO  - Internist (Berl). 2016 Mar;57(3):230-7. doi: 10.1007/s00108-016-0017-y.